Clinical Trials Browser

Phase 3 × OTHER_GOV × Imatinib Mesylate × Clear all

NCT00297570 2007-10-10

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

Phase 3 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive